Abstract: A lyophilisate having as an active ingredient flupirtine in base form or as a physiologically tolerated salt is suitable for producing a pharmaceutical composition for parenteral administration. The physiologically tolerated salt is an acid addition salt of flupirtine. The lyophilisate contains at least one additive selected from the group consisting of a cake-forming agent, an antioxidant, and a detergent. In a process for producing a flupirtine-containing pharmaceutical composition for parenteral administration, a flupirtine-containing lyophilisate is dissolved in at least one solvent that is an aqueous medium or an organic solvent or a combination thereof to obtain a liquid pharmaceutical composition ready for use. In a process for producing a flupirtine-containing lyophilisate, a flupirtine solution is prepared by dissolving flupirtine base in an aqueous medium and the flupirtine solution is freeze dried.

Abstract: The invention relates to a process of making an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient wherein when the dosage form is a granule or a pellet. The formulation is made by melting the oral formulation and granulating or pelletizing the melt.

Abstract: The invention is a delayed release pharmaceutical composition which comprises calcium valproate, one or more acrylic polymers, and on or more sugar esters, a process for making, and the treatment of epilepsy, migraine, and manic-depression therewith.

Abstract: The invention relates to an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient wherein when the dosage form is a granule or a pellet, the formulation is made by melting the oral formulation, and granulating or pelletizing the melt.

Abstract: An aqueous solution of from about 1 mg/ml to about 5 mg/ml mitoxantrone.HCl, from about 0.01% wt. to about 0.15% wt. based on the solution of sodium edetate, sodium chloride, sodium acetate, and acetic acid, and a process for preparing the same.